Youssef Rddad

Florida

Staff Writer at Oncology News Central

Journalist, composer, @theadvocatebr, @arkansasonline and @AP alumn.

Featured in: Favicon

theadvocate.com Favicon

msn.com

foxnews.com Favicon

washingtonpost.com Favicon

time.com

latimes.com Favicon

sfgate.com Favicon

usnews.com Favicon

yahoo.com (+1) Favicon

apnews.com + 111 more

Articles

Cancer Drugs’ Sexual Toxicity Spurs “Call to Action” for Oncologists

1 week ago | oncologynewscentral.com | Carina Storrs |Youssef Rddad

More work is needed to adequately address sexual and reproductive toxicity in patients receiving treatment for cancer, according to a comment recently published in Lancet Oncology. David J. Benjamin, MD, of the Hoag Family Cancer Institute in Newport Beach, California, and Mark P.
FDA Approves Nivolumab (Opdivo) Plus Ipilimumab (Yervoy) for First-Line Metastatic Liver Cancer

1 week ago | oncologynewscentral.com | Youssef Rddad |Emily Bader

On April 11, the U.S. Food and Drug Administration (FDA) approved the use of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with previously untreated unresectable or metastatic hepatocellular carcinoma (HCC). The approval follows a similar regulatory move by the European Commission last week. The FDA based its approval on data from the CheckMate 9DW trial, the results of which were presented as a late-breaking abstract at the 2024 American Society of Clinical Oncology Annual Meeting.
FDA Fully Approves Larotrectinib for NTRK-Positive Solid Tumors

2 weeks ago | oncologynewscentral.com | Ryan Syrek |Youssef Rddad

The U.S. Food and Drug Administration (FDA) granted full approval to larotrectinib (Vitrakvi) for adults and children with NTRK fusion–positive solid tumors that are metastatic, unresectable, or have no other treatment options, drugmaker Bayer announced in an April 10 news release. Regulators based the latest decision on pooled data from the three single-group studies. These included results from the phase 1 LOXO-TRK-14001 trial, the phase 1/2 SCOUT trial, and the phase 2 NAVIGATE trial.
FDA Approves Nivolumab (Opdivo) Plus Ipilimumab (Yervoy) for Advanced Colorectal Cancer

2 weeks ago | oncologynewscentral.com | Youssef Rddad

On April 8, the U.S. Food and Drug Administration approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for adults and children aged 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).
Oncologists Shouldn’t Overlook Dental Concerns, Experts at NCCN 2025 Stress

2 weeks ago | oncologynewscentral.com | Youssef Rddad

At the 2025 National Comprehensive Cancer Network (NCCN) Annual Meeting, experts underscored the critical need for oncologists to integrate dental care into cancer treatment protocols and collaborate with dental specialists to prevent serious complications.
Practice Change for Cancer Patients at Risk for Venous Thromboembolism

2 weeks ago | medcentral.com | Patrice Wendling |Suchandrima Bhowmik |Youssef Rddad

Extended treatment with a lower dose of apixaban (Eliquis) is noninferior to the full dose at preventing recurrent venous thromboembolism (VTE) with less bleeding in patients with active cancer who have completed at least 6 months of anticoagulation therapy, results from the API-CAT trial show. Findings were presented at the American College of Cardiology Annual Scientific Session and simultaneously published in the New England Journal of Medicine.
Cancer Guidelines Evolve as NCCN Turns 30

2 weeks ago | oncologynewscentral.com | Youssef Rddad

The National Comprehensive Cancer Network (NCCN) is marking its 30th anniversary in 2025, having grown from a small alliance of 13 centers to a global leader in cancer care guidelines. Founded in response to the need for standardized care in the United States, NCCN has expanded its mission to include global access to high-quality, patient-centered cancer treatment and prevention.
Mental Health in Oncology Remains Unmet Need, Experts at NCCN 2025 Argue

3 weeks ago | oncologynewscentral.com | Youssef Rddad

A panel of experts underscored the need for mental health integration and interdisciplinary collaboration in oncology care during a plenary session at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference. Moderated by Jessica Vanderlan, PhD, of Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in Saint Louis, Missouri, the panel brought together various perspectives in psychiatry and oncology.
NCCN Updates Guidance for Immune Checkpoint Inhibitors: What to Know

3 weeks ago | oncologynewscentral.com | Youssef Rddad

Immune checkpoint inhibitors (ICIs) have increasingly shifted toward frontline treatment in oncology, raising questions about how to optimize their use and manage associated toxicities to keep patients on treatment.
How Should Oncologists Handle Unusual Patient Claims and Requests?

3 weeks ago | oncologynewscentral.com | Erin Frances Cobain |Manali Bhave |Stephanie Graff |Youssef Rddad

This transcript has been lightly edited for clarity. Stephanie Graff, MD: Hi, my name is Dr. Stephanie Graff and I’m the director of breast medical oncology at the Legorreta Cancer Center at Brown University in Providence, Rhode Island. It is an honor to be here today with my two cohosts: Dr. Erin Cobain? Erin Frances Cobain, MD: Hi, everyone, I am Dr. Erin Cobain. I am also a breast cancer medical oncologist and also do cancer genetics work here at the University of Michigan Rogel Cancer Center.